- Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectations Gallery
Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectations
Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectations
Please login to view this page.
EU | EMA Publishes New GVP Module on Pregnancy and Breastfeeding — Implications for Real-World Safety Research
Please login to view this page.
EU | ICH M14 Guideline on Non-Interventional Studies Using RWD Becomes Legally Effective — Implications for EU Pharmacovigilance Practice
Please login to view this page.
EU | Updates to Regulation (EU) No 520/2012 — Key Pharmacovigilance Changes Applicable from 12 February 2026
Please login to view this page.





